358 related articles for article (PubMed ID: 31634532)
1. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
2. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
[TBL] [Abstract][Full Text] [Related]
3. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.
Pencek R; Marmon T; Roth JD; Liberman A; Hooshmand-Rad R; Young MA
Diabetes Obes Metab; 2016 Sep; 18(9):936-40. PubMed ID: 27109453
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
5. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
Hameed B; Terrault NA; Gill RM; Loomba R; Chalasani N; Hoofnagle JH; Van Natta ML;
Aliment Pharmacol Ther; 2018 Mar; 47(5):645-656. PubMed ID: 29333665
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
[TBL] [Abstract][Full Text] [Related]
12. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Zhao J; Li B; Zhang K; Zhu Z
Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis.
Männistö VT; Simonen M; Soininen P; Tiainen M; Kangas AJ; Kaminska D; Venesmaa S; Käkelä P; Kärjä V; Gylling H; Ala-Korpela M; Pihlajamäki J
J Lipid Res; 2014 Dec; 55(12):2676-84. PubMed ID: 25344588
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
16. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
Koren MJ; Kereiakes D; Pourfarzib R; Winegar D; Banerjee P; Hamon S; Hanotin C; McKenney JM
J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26586732
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
[TBL] [Abstract][Full Text] [Related]
18. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
19. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
[TBL] [Abstract][Full Text] [Related]
20. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia.
Goldberg RB; Rosenson RS; Hernandez-Triana E; Misir S; Jones MR
Diab Vasc Dis Res; 2013 May; 10(3):256-62. PubMed ID: 23152373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]